

Bayesian Modeling of Spatiotemporal patterns of TB-HIV co-infection risk in Kenya

Verrah A Otiende (✉ verrahodhiambo@gmail.com)

Pan African University <https://orcid.org/0000-0001-6147-3547>

Thomas N O Achia

University of the Witwatersrand Faculty of Health Sciences

Henry G Mwambi

University of KwaZulu-Natal

Research article

Keywords: Bayesian modeling, TB-HIV co-infection, co-epidemic burden, Kenya

Posted Date: October 22nd, 2019

DOI: <https://doi.org/10.21203/rs.2.9411/v3>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on October 28th, 2019. See the published version at <https://doi.org/10.1186/s12879-019-4540-z>.

1 **Bayesian Modeling of Spatiotemporal patterns of TB-HIV co-** 2 **infection risk in Kenya**

3 Verrah Otiende^{1*}, Thomas Achia², Henry Mwambi³

4 *Correspondence: otiende.verrah@students.jkuat.ac.ke; verrahodhiambo@gmail.com

5 **Abstract**

6 **Background**

7 Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) diseases are globally acknowledged as
8 public health challenges exhibiting adverse bidirectional relations due to the co-epidemic overlap. To
9 understand the co-infection burden we used case notification data to generate spatiotemporal maps to
10 describe risk patterns for further epidemiologic investigations. These model maps are relevant for
11 geographically targeting interventions towards suppressing co-infection

12 **Methods**

13 We analyzed the TB and TB-HIV case notification data from the Kenya national TB control program
14 aggregated for forty-seven counties over a seven-year period (2012 – 2018). Using the Integrated Nested
15 Laplace Approach (INLA), we modeled the risk of TB-HIV co-infection. Six competing models with
16 varying space-time formulations were compared to determine the best fit model. We assessed the space-
17 time patterns of coinfection risk by mapping the posterior marginal from the best fit model.

18 **Results**

19 Of the total 608312 TB case notifications, 194129 were HIV co-infected. The proportion of TB-HIV co-
20 infection was higher in female (39.7%) than to male (27.0%). A significant share of the co-infection was
21 among adults aged 35 to 44 years (46.7%) and 45 to 54 years (42.1%). Based on the Bayesian Defiance
22 Information (DIC) and the effective number of parameters (pD) comparisons, the spatiotemporal model 3b

23 was the best in explaining the geographical variations in TB-HIV coinfection. The model results suggested
24 that the risk of TB-HIV coinfection was influenced by infrastructure index (5.75, Credible Interval (Cr.I) =
25 (1.65, 19.89) and gender ratio ($5.81e^{-04}$, Cr.I = ($1.06e^{-04}$, $3.18e^{-03}$)). The lowest and highest temporal risks
26 were in the years 2016 at 0.9 and 2012 at 1.07 respectively. The spatial pattern presented increased co-
27 infection risk in various counties. For the spatiotemporal interaction, few counties had a probability of risk
28 greater than 1 that varied in different years.

29 **Conclusions**

30 TB-HIV co-epidemic in Kenya is at a critical point portending a dual endemic challenge for many years to
31 come. Integration of care for both TB and HIV using a single facility and single health provider in each
32 county will enable proper monitoring of the co-infection trends and subsequently significant reduction of
33 HIV burden amongst TB patients and TB burden amongst HIV patients

34 **Keywords**

35 Bayesian modeling, TB-HIV co-infection, co-epidemic burden, Kenya

36 **Background**

37 Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) diseases have a co-epidemic relation such
38 that the chronic immune prompt arising from TB disease hastens HIV disease advancement (1,2). Both the
39 TB and HIV pathogens interact collectively, accelerating the progress of illness thereby increasing the
40 chances of death (3). Globally, TB and HIV exhibit an adverse bidirectional interaction because of the co-
41 epidemic overlap. The risk of TB infection developing into TB disease is between 16-27 times higher in
42 HIV infected persons (4). TB can occur both in the early stages and through all stages of HIV infection
43 although the risk intensifies soon after infection with HIV (5).

44 Under the same degree of exposure, there exists no irrefutable evidence that HIV positive persons are more
45 likely to acquire TB infection than HIV negative persons (6). However, the risk of rapid progression once
46 TB infection occurs is greater among persons living with HIV infection (7,8). The lifetime risk for HIV

47 negative individuals to develop active TB from latent TB is about 5% to 10%, whereas, for persons living
48 with HIV, the same percentage holds but annually opposed to lifetime (9). Studies by (10) and (11) in
49 various outbreak settings confirms that HIV co-infection does intensify the progression of latent TB to
50 active TB disease. The diagnosis of TB in the HIV epidemic remains extremely challenging because of the
51 difficulty in differentiating between reactivation and recent infections (12). The risk of infection or
52 reinfection is dependent on the source case numbers in various congregate settings including households
53 and health-care facilities (5)

54 The disparity for TB infections between persons with and without HIV infection remains a global concern
55 especially because of the high incidence rate among HIV infected persons (13). A study by (14) observed
56 that the prevalence of HIV infections for persons reporting prior TB disease was 33.2% compared to 5.1%
57 in persons without prior TB. Another study by (13) confirmed that TB disease incidence among HIV
58 infected persons was still eight times higher than in persons without HIV. In the year 2015, the global
59 estimation of TB disease was 10.4 million of which 11% were HIV positive (15). Approximately 60% of
60 the TB/HIV co-infected patients received neither diagnosis nor treatment leading to 390,000 TB related
61 deaths (16).

62 Globally, sub-Saharan Africa accounts for the largest percentage of the dual epidemic with co-morbidity
63 from TB-HIV remaining a critical public health challenge (14). In essence, more people die from TB than
64 HIV associated infections (17). In 2016 alone, the SSA region accounted for an estimated 86% of HIV-
65 linked TB deaths (18). Kenya is one of the countries in SSA severely hit by the dual epidemic and appears
66 among the WHO high TB and TB-HIV burden countries ranking 13 out of the 22 countries globally (19,20).
67 The impact of TB-HIV co-infection in Kenya is evident mainly because of the complications in diagnosis
68 and management. Equally, the HIV surveillance on TB patients and the TB surveillance on HIV patients in
69 Kenya relies primarily on the self-reported cases from health facilities as a surrogate measure of the actual
70 co-endemic. The two surveillance systems are not integrated making it a challenge to profile the actual co-
71 infection burden. Therefore, the feasibility of using case notifications instead of population-based studies
72 to capture the valid spatiotemporal co-infection incidence estimates of the co-epidemic is unknown

73 Against this background, we investigate the geographical variation and co-infection burden using the case
74 notification data for a 7-year period and characterize the areas with unusually high relative risks. We utilize
75 the space-time disease mapping models which allow for the concurrent study of persistent and unusual co-
76 infection trends, thus offering additional benefits over purely spatial disease mapping models (21,22). These
77 model-maps describe new exposure hypotheses that warrant further epidemiologic investigations in areas
78 with unusual case notification levels and ultimately inform relevant geographically based interventions and
79 resource allocation towards suppressing further infections.

80 **Methods**

81 **Data Sources**

82 We conducted this study through extensive analysis of TB case notification data from the Kenya national
83 TB control program database. The database is an elaborate and robust surveillance system that captures
84 case notification data from the health facilities in every county and updates the records on the national grid.
85 For the process of data capture into the surveillance system, the National TB program adapted both the
86 recording and reporting tools from WHO. The WHO recommends systematic screening for HIV among TB
87 patients; our dataset captures the HIV status of all the TB case notifications. We analyze the data aggregated
88 at the county level.

89 **Model Description**

90 For the county s in the year t , we modelled the TB-HIV cases notification y_{st} as

$$91 \quad y_{st} \sim \text{Poisson}(\lambda_{st})$$

92 We assumed our count data follows the Poisson distribution where the log of the relative risks was the focus
93 of modeling. We defined the mean λ_{st} in terms of the unknown relative risk and expected number of co-
94 infection cases i.e. $\lambda_{st} = \rho_{st} E_{st}$.

95 We defined the population at risk of TB-HIV co-infection are the TB cases. We computed the expected
96 counts of co-infection cases E_{st} per county per year. These counts represent the number of cases one would

97 expect if the population of county s has a similar behavior to the standard population. Our statistical
 98 consideration for the standard population N was the average of the pooled TB cases, i.e. $N = \frac{P}{Y}$, where P is
 99 the total number of TB cases at risk of co-infection and Y is the number of years, which is seven for this
 100 study. We calculated the crude rate as $R_{st} = \frac{\sum X_{st}}{P_{st}}$, where $\sum X_{st}$ and P_{st} are the number of co-infection cases
 101 and number of TB cases in county s , year t respectively. We then multiplied the crude rate by the standard
 102 population to obtain the expected number of co-infection cases

$$103 \quad E_{st} = R_{st} \times N$$

104 We expressed the linear predictor on the logarithmic scale, $\eta_{st} = \log(\rho_{st})$ which is the recommended
 105 invertible link function for the Poisson family of distributions. We compared the spatiotemporal disease
 106 models discussed by (23). The models differed in their formulation of the space-time structure and the
 107 inclusion or not of the covariates. Model 1a applied the classical parametric formulation of (24) on the
 108 linear predictor, which we expressed as

$$\eta_{st} = \alpha + v_s + v_t + (\rho + \delta_s) \times Z_t \quad (1a)$$

109 The formulation included the spatially structured (v_s) and unstructured (v_t) random effects, the global
 110 linear time trend effect ($\rho \times Z_t$). The term $\delta_s \times Z_t$ is the interaction term between space and time defining
 111 the difference between ρ and the area specific time trend. It is referred to as the differential trend of the s^{th}
 112 area (23,24). The term Z_t is a vector of temporal weights and the intercept α quantifies the average co-
 113 infection rate in all the 47 counties. Each spatial unit has its own time trend with a spatial intercept ($\alpha +$
 114 $v_s + v_t$) and a slope ($\rho + \delta_s$). This model assumes a linear time trend in each spatial unit. We estimated
 115 the parameters $\theta = \{\alpha, \rho, v, v, \delta\}$ and the hyper-parameters $\psi = \{\tau_v, \tau_v, \tau_\delta\}$.

116 The model 1b included the covariates to the model 1a thereby estimating $\theta = \{\alpha, \beta, \rho, v, v, \delta\}$ and $\psi =$
 117 $\{\tau_v, \tau_v, \tau_\delta\}$. The model expression was

$$\eta_{st} = \alpha + \sum \beta_i x_i + v_s + v_t + (\rho + \delta_s) \times Z_t \quad (1b)$$

118 The model 2a used the dynamic non-parametric formulation on the linear predictor

$$\eta_{st} = \alpha + u_s + v_s + \gamma_t + \phi_t \quad (2a)$$

119 The terms α, u_s and v_s are similar to the formulation in the first model, additionally, the terms γ_t and ϕ_t
 120 represents the temporally structured and unstructured random effect respectively. The model assumes a
 121 non-parametric time trend. In this formulation, $\theta = \{\alpha, v, u, \gamma, \phi\}$ and $\psi = \{\tau_v, \tau_u, \tau_\gamma, \tau_\phi\}$.

122 The model 2b incorporated the covariates to the model 2a to estimate $\theta = \{\alpha, \beta, v, u, \gamma, \phi\}$ and $\psi =$
 123 $\{\tau_v, \tau_u, \tau_\gamma, \tau_\phi\}$. We expressed model 2f as

$$\eta_{st} = \alpha + \sum \beta_i x_i + u_s + v_s + \gamma_t + \phi_t \quad (2b)$$

124 Our model 3a expanded the model 2a by allowing a space-time interaction to explain for the difference in
 125 the time trend of TB-HIV coinfection for the diverse counties.

$$\eta_{st} = \alpha + u_s + v_s + \gamma_t + \phi_t + \delta_{st} \quad (3a)$$

126 For this model, $\theta = \{\alpha, v, u, \gamma, \phi, \delta\}$ and $\psi = \{\tau_v, \tau_u, \tau_\gamma, \tau_\phi, \tau_\delta\}$. We defined δ_{st} as the interaction
 127 between v_s and ϕ_t consequently assuming no interaction between v_s and γ_t therefore $\delta_{st} \sim N(0, \tau_\delta)$.

128 The final model 3b incorporated the covariates to the model 3a to estimate $\theta = \{\alpha, \beta, v, u, \gamma, \phi, \delta\}$ and $\psi =$
 129 $\{\tau_v, \tau_u, \tau_\gamma, \tau_\phi, \tau_\delta\}$. We formulated the model as

$$\eta_{st} = \alpha + \sum \beta_i x_i + u_s + v_s + \gamma_t + \phi_t + \delta_{st} \quad (3b)$$

130 To assess the performance of these six models, we used the DIC taking into consideration the complexity
 131 of the models. We selected the model with the lowest DIC as the best-fit model

132 **Baseline predictor variables**

133 The set of baseline predictors were poverty index, infrastructure index, health index, education index,
 134 gender ratio, dependency ratio, and Gini coefficient. The measures of these predictors were obtained from
 135 (25) and (26). These predictors are standard indices used to establish the comparative level of development
 136 of different counties in Kenya. The computation of these indices are further elaborated in the reports from

137 (25) and (26). All these predictor variables were fitted in the models 1b, 2b and 3b but only the significant
138 ones were considered in the discussion.

139 The poverty index provides a measure on the inadequate consumption of basic services and fundamental
140 rights. In other words, it estimates the disparities in resource expenditures for each county. The
141 infrastructure index captures access to natural resources, economic growth and innovative planning. The
142 health index measures access to medical services, adequate medical work force and improved medical
143 productivity. The education index captures the literacy attainment, completion and dropout rate. The gender
144 inequality index reflects the bias in reproductive health, empowerment and labor market between men and
145 women. The dependency ratio gives an indication on the burden of the working population and government
146 to support the non-working population who are either too young or too old. The Gini coefficient compares
147 the distribution of income in the entire population of any given county. It is based on the Lorenz curve and
148 varies between 0 (complete equality) and 1 (complete inequality).

149 **Statistical Analysis**

150 For the demographic characterization of the case notifications, we compared the summaries of TB cases
151 with and without HIV infections. We stratified the data based on HIV status and performed the chi-square
152 test to determine the association between HIV status and each of the demographic variables TB-type, age,
153 gender, and patient type. All the p-values were two-tailed with values less than 0.05 considered being
154 statistically significant. The TB type classification was either pulmonary TB or extra-pulmonary TB.
155 Pulmonary TB referring to a patient with TB disease involving the lung parenchyma whereas the extra-
156 pulmonary TB involves any organ other than the lungs. For the patient type, we had five categories; the
157 first was the default category for patients who defaulted the TB therapy then experienced recurrence. The
158 second was the failed category for patients previously diagnosed with TB but never took on the therapy.
159 The third category was for newly diagnosed patients without previous TB diagnosis or therapy. The relapse
160 case was the fourth category whereby patients were previously diagnosed, treated of TB and completed the
161 TB therapy but experienced a recurrence. The fifth and final category were the cases transferred in from
162 other health facilities to continue with the therapy.

163 Using the Integrated Nested Laplace Approach (INLA), we fitted the case notification data to our
164 spatiotemporal disease models to determine the best fit. We assessed the nature of the response variables
165 on our baseline predictors. We specified the Besag-York-Mollie (BYM) prior on v_s using the intrinsic
166 conditional autoregressive structure (iCAR) $v_{s_i} | v_{s_i \neq s_j} \sim N\left(\frac{\sum_{j \in N(s)} v_{s_j}}{\#N(s)}, \frac{\sigma_v^2}{\#N(s)}\right)$ where $\#N(s)$ is the number
167 of neighbors sharing boundaries with the county s_i . The BYM model allows us to capture both the
168 heterogeneity (variability) and clustering of diseases risk simultaneously. We then used the exchangeable
169 prior on v_s , that is $v_s \sim N(0, \sigma_v^2)$. We modelled γ_t using a random walk specified through the temporal
170 adjacency structure, which is analogous to the spatially structured random effects specification as it borrows
171 strength from adjacent time periods. The temporally unstructured random effect ϕ_t was modelled using the
172 Gaussian exchangeable prior $\phi_t \sim N(0, \tau_\phi)$. We defined improper priors for the intercept and regression
173 coefficients of the fixed effects as $\alpha \sim N(0,0)$ and $\beta \sim N(0, 0.001)$ respectively. For the distribution of the
174 hyper-parameters, we assumed the default specifications of INLA whereby we assigned minimally
175 informative priors on the log of the precision of both the structured and unstructured effects $\psi \sim (1, 0.0005)$.

176 **Results**

177 **Demographic characterization of TB-HIV case notification in Kenya, 2012-2018**

178 Of the total 608312 TB case notification for the period 2012-2018 included in the study, 194129 cases were
179 HIV co-infected, 391030 cases were HIV uninfected and 23153 cases were unaware of their HIV status
180 because either the HIV test was not done or they declined to be tested. The demographic characteristics of
181 TB patients stratified by HIV status are in Table 1. The TB case notification decreased from 99586 (16.4%)
182 in 2012 to 78318 (12.6%) in 2016 but increased to 85886 (14.1%) in 2017 and 83324 (13.7%) in 2018.
183 Similarly, the co-infection cases decreased from 36135 (36.3%) in 2012 to 21896 (26.3%) in 2018. The
184 chi-square test showed that HIV status was positively associated to age, time of case notification, type of
185 TB, gender and TB patient type (p-value <0.01)

186 The male TB case notification exceeded the female but the proportion of TB-HIV co-infection was higher
187 in female cases (39.7%) as compared to male cases (27.0%). The temporal trend of co-infection risk was
188 consistently higher in women (Figure 1) whereas the spatial pattern was widespread in males compared to
189 the female. The counties with high co-infection burden for both male and female were Homabay, Siaya,
190 Kisumu, Migori and Busia counties (Figure 2). A significant share of the co-infection was among adults
191 between the ages 35 to 44 years (46.7%) and 45 to 54 years (42.1%). Patients aged below 25 years and
192 above 54 years registered a considerably lower co-infection risk over time (Figures 3). The spatial patterns
193 based on age-categories showed a widespread co-infection risk pattern for the ages 25-34 followed by 35-
194 44 years (Figure 4). These age categories and generally the most sexually active age ranges, which puts
195 them at higher risk of co-infection.

196 The proportion of extra-pulmonary TB cases co-infected with HIV (35.6%) also surpassed that of
197 pulmonary TB (31.2%). Looking at the patient types, the 194129 TB-HIV co-infection cases were
198 composed of 171115 (31.0%) new TB infections, 17174 (42.9%) TB relapse cases, 457 (29.5%) TB therapy
199 failure cases, 3336 (37.5%) defaulted cases and 2047 (30.9%) transferred in cases.

200 **Model comparison**

201 In Tables 2 and 3 we present the results of the six hierarchical models including the Deviance Information
202 Criterion (*DIC*), the effective number of parameters (*pD*) and the mean deviance (\check{D}). We compared the
203 spatiotemporal disease models discussed by (23), which differed in their formulation of the space-time
204 structure and the inclusion or not of the fixed effects. The values of *pD* penalizes the complexity of the
205 model and smaller values indicates a parsimonious model. For Poisson likelihoods, the *pD* should be
206 approximately equal to the number of observations (27); that is $47 \times 7 = 329$. Model 1a has the smaller
207 *pD* than the number of observations and the biggest *DIC*, indicating a clear lack of fit. Both criteria thus
208 point to the model 3b being the best fitting model. In this model, the infrastructure index (5.75, Cr.I =
209 (1.65, 19.89)) and gender ratio ($5.81e^{-04}$, Cr.I = ($1.06e^{-04}$, $3.18e^{-03}$)) were significantly associated
210 with TB-HIV co-infection. In the remaining sections, we focus on presenting the results on the model 3b.

211 **Temporal characteristics of TB-HIV co-infection epidemics**

212 The temporal trend in TB-HIV co-infection relative risks from 2012 – 2018 are in Figure 5. The co-infection
213 risk trend shows an initial steady decrease between 2012 and 2016 then a sharp increase in 2017 that slightly
214 decreases in 2018. The lowest risk of 0.9 was in the year 2016 while the highest risk of 1.07 was in the year
215 2012.

216 **Spatial patterns of TB-HIV co-infection epidemic**

217 The spatial map in Figure 6 and relative risk plot in Figure 7 present the cumulative predicted values of TB-
218 HIV coinfection risk over a 7-year period (2012 – 2018) per county. There were 12 counties out of the 47
219 with high co-infection risk evidenced by values greater than 1. Most of these high-risk counties were
220 towards the further west of Kenya; Homabay County was leading followed by Siaya, Kisumu, Migori and
221 Busia counties

222 Figure 8(a) shows the spatial pattern of the posterior mean for the country-specific relative risk ($\zeta_s =$
223 $e^{(\xi_s + \nu_s + \nu_s)}$) of TB-HIV co-infection compared to the whole of Kenya while Figure 8(b) presents the
224 measure of uncertainty associated with the posterior means $\zeta_s: P(\zeta_s > 1|y)$. It is evident that there is an
225 increased co-infection risk in a number of counties characterized by a spatial relative risk above one and a
226 posterior probability of the relative risk above 0.8 indicating a high level of associated certainty.

227 **Spatiotemporal trends of TB-HIV co-infection epidemics**

228 The probability maps for the space-time interaction relative risk estimates greater than one, $P(e^{\delta_{st}} > 1|y)$,
229 for the seven years are in Figure 9. These are the exceedance probabilities useful for assessing unusual
230 elevation of coinfection risk over the 7-year period of study. In relation to TB-HIV co-infection the
231 specification for the spatiotemporal interaction assumed that the residual coinfection patterns were not
232 correlated for adjacent county-year. This is evident as our results showed only a few counties had a
233 probability of the relative risk being greater than 1 and they varied in different years.

234 **Discussion**

235 The surveillance data from the National TB program gives deep insights on the TB-HIV co-epidemic. This
236 study established that 96% of the TB case notifications had documented HIV test results, which is greater
237 than the WHO's global estimate of 64% in 2017 and that of the African region (86%) (28). The significant
238 upturn in the HIV screening practices for every TB case notifications in Kenya could be attributed to the
239 commitment from the National TB program and the health professionals in communication and social
240 mobilization for early diagnosis and therapy uptake. Similar observations were reported in Ghana (29) and
241 Ethiopia (30). Globally, Kenya registered 8% TB decline rate per year from 2013 to 2017 amongst other
242 high TB burden countries including the Russian Federation (13%), Ethiopia (12%), Sierra Leone (10%)
243 and Viet Nam at 8% (28).

244 Our findings on the number of TB case notifications per year for the period 2012 to 2018 showed a steady
245 reduction for the period 2012 – 2016 then a significant rise in 2017 and a slow decrease in 2018. The
246 temporal trend of the coinfection relative risk for the entire country followed a similar pattern as the TB
247 case notifications. From 2012 – 2016, there was a clear downward relative risk trend then a steep upward
248 risk for the year 2017 – 2018. This could be because of either improvement in TB cases detection or
249 surveillance biases due to spatial heterogeneity in the co-infection dynamics, an observation that is in accord
250 with the conclusions of (31). To maintain the consistent TB decline rates, supplementary efforts to support
251 TB-HIV collaborative activities towards reducing the burden of HIV in TB patients are critical.

252 The co-infection cases were higher in patients aged between 35 – 54 years with new cases of TB infection.
253 Similarly, the co-infection risk was higher for the same age bracket, which implied that co-infection was
254 more common in the sexually active age group. These findings were contrary to the findings by (32) and
255 (29) who observed that high rates of TB-HIV co-infections were in younger patients (<15 years of age) but
256 consistent to several other studies (30,33–36). The study also revealed that a larger proportion of the HIV
257 co-infected cases had extra-pulmonary TB conforming to (37) and (34) who found that the risk of extra-
258 pulmonary TB was higher in HIV co-infected cases majorly because of delayed diagnosis especially for the
259 sputum smear-negative

260 In our study, the male TB cases significantly exceeded female cases. However, the risk of co-infection was
261 consistently higher in females than in males for the period 2012 – 2018. The findings conform to a number
262 of studies showing that females bear a disproportionate burden of TB-HIV co-infection in SSA (14,38–41).
263 The larger TB case notification among the male could be because of the barriers the female encounter in
264 seeking care for and diagnosis of TB or could reflect more complete registration for treatment by the male
265 (42). In other studies by (34), the prevalence of co-infection was much higher among males in most
266 countries in Sub-Saharan Africa whereas in all other countries there was no significant difference in the
267 gender ratio. However, the case notification data alone are insufficient to determine whether the gender
268 ratio reflect an excess in the co-infection burden among men or a disadvantage among women in seeking
269 and accessing TB care.

270 Having proper infrastructure in place is the foundation for planning, delivering and evaluating public health
271 services. The country infrastructure ranking in (26) showed counties with infrastructure index below the
272 national average of 0.41 were classified as the most marginalized. In our study, it was evident that counties
273 in the western region of Kenya, that is Homabay, Siaya, Kisumu, Migori, Busia, and Vihiga, have
274 unresolved co-infection dynamics that is echoed by their infrastructure index. Their patterns of co-infection
275 also reinforced the fact that counties with high HIV prevalence also post high TB disease burden (43,44)
276 with exception of a few like Wajir, Lamu, Isiolo and West Pokot that have lower HIV incidence rate but
277 high TB burden. We attribute these exceptions to unsuccessful treatment critical to arresting TB re-
278 infections and new infections. In terms of competitive exclusion, TB can exist in places where HIV is of
279 low incidence

280 Although TB disproportionately affects persons living with HIV, most of the transmission is by persons
281 without HIV, who typically remain transmissible for a longer period. Since delayed diagnosis influences
282 the prolongation of infectiousness and effective treatment rapidly attenuates infectiousness (45,46),
283 initiatives to reduce TB incidence in the general population can help prevent new infections among persons
284 living with HIV.

285 The primary limitation of the study is using case notification data as a surrogate measure of the general
286 population at risk. Case notifications are data from specific subpopulations who seek treatment and care
287 from health facilities; these are geographically representative of nearby populations. Whereas this kind of
288 data is not completely spatially random for the co-epidemic burden, it still captures the spatiotemporal
289 patterns of incidence risk, which is the ultimate goal of this study.

290 **Conclusion**

291 Our study demonstrates the potential utility of case notification data in providing robust estimates for the
292 broad spatiotemporal structure of the TB-HIV co-epidemic. The findings have shown that the high burden
293 counties for TB-HIV co-infection are consistent with findings from previous work done on high burden
294 counties for HIV. This suggests that the TB-HIV co-epidemic in Kenya is still at a critical point portending
295 a dual endemic challenge for many years to come. Much as HIV is a serious challenge in the management
296 of TB, the national response to TB-HIV coinfection promotes HIV testing among TB patients as a strategy
297 to reduce TB transmission. However, the government of Kenya needs to combine surveillance systems for
298 the TB and HIV National programs to optimize the TB-HIV coinfection case notification processes at all
299 levels. With integrated case notification systems at the health facility levels, there will be complete data
300 capture on co-infection incidences and outcomes. Integration of care for both TB and HIV using a single
301 facility and single health provider in each county will enable proper monitoring of the co-infection trends,
302 which will guide policy decisions on access to health care and relevant public health interventions. This
303 will also ensure adequate resource allocation to cause a significant impact on the reduction of HIV burden
304 amongst TB patients and TB burden amongst HIV patients

305 **List of abbreviations**

306 BYM Besag-York-Mollie

307 CI Confidence Interval

308 \check{D} mean deviance

- 309 DIC Deviance Information Criterion
- 310 FEM Fixed Effects Model
- 311 HIV Human Immunodeficiency Virus
- 312 iCAR intrinsic Conditional Autoregressive Model
- 313 INLA Integrated Nested Laplace Approach
- 314 NLTP National Tuberculosis, Leprosy and Lung Disease Program
- 315 pD effective number of parameters
- 316 TB Tuberculosis

317 **Declarations**

318 **Ethics approval and consent to participate**

319 This study used data with all participant identifiers removed. Ethical permission for use of the data in the
320 present study was obtained from National Tuberculosis, Leprosy and Lung Disease Program (NLTP) -
321 Kenya.

322 **Consent for publication**

323 Not applicable

324 **Availability of data and material**

325 The datasets used and/ or analyzed during the current study are available from the corresponding author on
326 reasonable request.

327 **Competing interests**

328 The authors declare that they have no competing interests.

329 **Funding**

330 The authors would like to thank the African Union and Pan African University Institute of Basic Sciences
331 Technology and Innovation (PAUISTI) for funding the study through VO's Ph.D. work.

332 **Authors' contributions**

333 VO conceived, designed the study and wrote the first draft of the manuscript. VO and TO analyzed data.
334 HM contributed to data analysis. All authors contributed to reviewing literature, interpretation of the results
335 and writing of the manuscript. All authors read and approved the final manuscript.

336 **Acknowledgments**

337 The authors sincerely thank the National Tuberculosis, Leprosy and Lung Cancer Program (NLTP) for
338 providing the data used in this study. The authors acknowledge the help of Prof Gabriel Magoma for
339 commenting on earlier drafts of the manuscript.

340 **Author's information**

341 ¹Department of Mathematical Sciences, Pan African University Institute of Basic Sciences Technology and
342 Innovation, Nairobi, Kenya

343 ²Epidemiology and Biostatistics Division, School of Public Health, University of the Witwatersrand,
344 Johannesburg, South Africa

345 ³School of Mathematics, Statistics & Computer Science, University of Kwa Zulu Natal, Pietermaritzburg,
346 South Africa

347 **References**

- 348 1. Kumar A, Kumar AM V, Gupta D, Kanchar A, Mohammed S, Srinath S, et al. Global guidelines
349 for treatment of tuberculosis among persons living with HIV: unresolved issues. *Int J Tuberc Lung*
350 *Dis.* 2012 May;16(5):573–8.

- 351 2. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, et al. Treatment of active
352 tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. *Clin Infect Dis*.
353 2010 May 1;50(9):1288–99.
- 354 3. Mayer KH, Hamilton CD. Synergistic Pandemics: Confronting the Global HIV and Tuberculosis
355 Epidemics. *Clin Infect Dis*. 2010 May 15;50(s3):S67–70.
- 356 4. WHO. Global Tuberculosis Report 2016. World Health Organization; 2016. 214 p.
- 357 5. Nkhoma K, Ahmed A, Ali Z, Gikaara N, Sherr L, Harding R. Does being on TB treatment predict
358 a higher burden of problems and concerns among HIV outpatients in Kenya? a cross-sectional
359 self-report study. *AIDS Care*. 2018 Jun 20;30(sup2):28–32.
- 360 6. Whalen CC, Zalwango S, Chiunda A, Malone L, Eisenach K, Joloba M, et al. Secondary attack
361 rate of tuberculosis in urban households in Kampala, Uganda. *PLoS One*. 2011 Feb
362 14;6(2):e16137.
- 363 7. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al. Early treatment
364 outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a
365 retrospective cohort study. *Lancet*. 2010 May 22;375(9728):1798–807.
- 366 8. Patel NR, Swan K, Li X, Tachado SD, Koziel H. Impaired M. tuberculosis-mediated apoptosis in
367 alveolar macrophages from HIV+ persons: potential role of IL-10 and BCL-3. *J Leukoc Biol*. 2009
368 Jul;86(1):53–60.
- 369 9. Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection.
370 *Nat Rev Microbiol*. 2017 Nov 7;16(2):80–90.
- 371 10. Van-Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment:
372 incidence, risk factors, and prevention strategies. *J Acquir Immune Defic Syndr*. 2011
373 Apr;56(4):349–55.
- 374 11. Gupta A, Wood R, Kaplan R, Bekker L-G, Lawn SD. Tuberculosis incidence rates during 8 years

- 375 of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the
376 community. *PLoS One*. 2012;7(3):e34156.
- 377 12. Winter JR, Adamu AL, Gupta RK, Stagg HR, Delpech V, Abubakar I. Tuberculosis infection and
378 disease in people living with HIV in countries with low tuberculosis incidence. *Int J Tuberc Lung*
379 *Dis*. 2018 Jul 1;22(7):713–22.
- 380 13. Yuen CM, Weyenga HO, Kim AA, Malika T, Muttai H, Katana A, et al. Comparison of trends in
381 tuberculosis incidence among adults living with HIV and adults without HIV--Kenya, 1998-2012.
382 *PLoS One*. 2014;9(6):e99880.
- 383 14. Mbithi A, Gichangi A, Kim AA, Katana A, Weyenga H, Williamson J, et al. Tuberculosis and
384 HIV at the national level in Kenya: results from the Second Kenya AIDS Indicator Survey. *J*
385 *Acquir Immune Defic Syndr*. 2014 May 1;66(Suppl 1):S106–15.
- 386 15. WHO. Global tuberculosis report 2015. 20th ed. World Health Organization; 2015. 192 p.
- 387 16. Trinh QM, Nguyen HL, Nguyen VN, Nguyen TVA, Sintchenko V, Marais BJ. Tuberculosis and
388 HIV co-infection-focus on the Asia-Pacific region. *Int J Infect Dis*. 2015 Mar;32:170–8.
- 389 17. Lin W-C, Lin H-H, Lee SS-J, Sy C-L, Wu K-S, Chen J-K, et al. Prevalence of latent tuberculosis
390 infection in persons with and without human immunodeficiency virus infection using two
391 interferon-gamma release assays and tuberculin skin test in a low human immunodeficiency virus
392 prevalence, intermediate tuberculosis-b. *J Microbiol Immunol Infect*. 2016 Oct;49(5):729–36.
- 393 18. Karo B, Krause G, Hollo V, van der Werf MJ, Castell S, Hamouda O, et al. Impact of HIV
394 infection on treatment outcome of tuberculosis in Europe. *AIDS*. 2016 Apr;30(7):1089–98.
- 395 19. Onyango DO, Yuen CM, Cain KP, Ngari F, Masini EO, Borgdorff MW. Reduction of HIV-
396 associated excess mortality by antiretroviral treatment among tuberculosis patients in Kenya.
397 Cameron DW, editor. *PLoS One*. 2017 Nov 16;12(11):e0188235.
- 398 20. Onyango DO, Yuen CM, Masini E, Borgdorff MW. Epidemiology of Pediatric Tuberculosis in

- 399 Kenya and Risk Factors for Mortality during Treatment: A National Retrospective Cohort Study. *J*
400 *Pediatr.* 2018 Oct;201:115–21.
- 401 21. Schrödle B, Held L. A Primer on Disease Mapping and Ecological Regression Using INLA.
402 *Comput Stat.* 2010;26(2):241–58.
- 403 22. Ugarte MD, Adin A, Goicoa T, Militino AF. On fitting spatio-temporal disease mapping models
404 using approximate Bayesian inference. *Stat Methods Med Res.* 2014;23(6):507–30.
- 405 23. Blangiardo M, Cameletti M, Baio G, Rue H. Spatial and spatio-temporal models with R-INLA.
406 *Spat Spatiotemporal Epidemiol.* 2013;4:33–49.
- 407 24. Bernardinelli L, Clayton D, Pascutto C, Montomoli C, Ghislandi M, Songini M. Bayesian analysis
408 of space - time variation in disease risk. *Stat Med.* 1995;14:2433–43.
- 409 25. HDR. Technical Note 3. 2015.
- 410 26. CRA. Creating a County Development Index to identify marginalized counties. Nairobi, Kenya;
411 2012. Report No.: 01.
- 412 27. Richardson S, Abellan JJ, Best N. Bayesian spatio-temporal analysis of joint patterns of male and
413 female lung cancer risks in Yorkshire (UK). *Stat Methods Med Res.* 2006;15(4):385–407.
- 414 28. WHO. TB burden estimates, notifications and treatment outcomes: For individual countries and
415 territories, WHO regions and the world. 2018.
- 416 29. Osei E, Der J, Owusu R, Kofie P, Axame WK. The burden of HIV on Tuberculosis patients in the
417 Volta region of Ghana from 2012 to 2015: implication for Tuberculosis control. *BMC Infect Dis.*
418 2017 Dec 19;17(1):504.
- 419 30. Tarekegne D, Jemal M, Atanaw T, Ebabu A, Endris M, Moges F, et al. Prevalence of human
420 immunodeficiency virus infection in a cohort of tuberculosis patients at Metema Hospital,
421 Northwest Ethiopia: a 3 years retrospective study. *BMC Res Notes.* 2016 Dec 29;9(1):192–8.

- 422 31. Sanchez M, Bartholomay P, Arakaki-Sanchez D, Enarson D, Bissell K, Barreira D, et al.
423 Outcomes of TB treatment by HIV status in national recording systems in Brazil, 2003-2008.
424 PLoS One. 2012;7(3):e33129.
- 425 32. Davy-Mendez T, Shiau R, Okada RC, Moss NJ, Huang S, Murgai N, et al. Combining
426 surveillance systems to investigate local trends in tuberculosis-HIV co-infection. *AIDS Care*. 2019
427 Feb 7;1–8.
- 428 33. Sánchez MS, Lloyd-Smith JO, Williams BG, Porco TC, Ryan SJ, Borgdorff MW, et al.
429 Incongruent HIV and tuberculosis co-dynamics in Kenya: Interacting epidemics monitor each
430 other. *Epidemics*. 2009 Mar;1(1):14–20.
- 431 34. Manjareeka M, Nanda S. Prevalence of HIV infection among tuberculosis patients in Eastern
432 India. *J Infect Public Health*. 2013 Oct;6(5):358–62.
- 433 35. van der Werf MJ, Ködmön C, Zucs P, Hollo V, Amato-Gauci AJ, Pharris A. Tuberculosis and
434 HIV coinfection in Europe: looking at one reality from two angles. *AIDS*. 2016;30(18):2845–53.
- 435 36. Chanda-Kapata P, Kapata N, Klinkenberg E, Grobusch MP, Cobelens F. The prevalence of HIV
436 among adults with pulmonary TB at a population level in Zambia. *BMC Infect Dis*.
437 2017;17(1):236.
- 438 37. Lee JY. Diagnosis and treatment of extrapulmonary tuberculosis. *Tuberc Respir Dis (Seoul)*. 2015
439 Apr;78(2):47–55.
- 440 38. Magadi MA. Understanding the gender disparity in HIV infection across countries in sub-Saharan
441 Africa: evidence from the Demographic and Health Surveys. *Sociol Health Illn*. 2011
442 May;33(4):522–39.
- 443 39. Sitienei J, Nyambati V, Borus P. The Epidemiology of Smear Positive Tuberculosis in Three
444 TB/HIV High Burden Provinces of Kenya (2003–2009). *Epidemiol Res Int*. 2013;2013:1–7.
- 445 40. Sia D, Onadja Y, Nandi A, Foro A, Brewer T. What lies behind gender inequalities in HIV/AIDS

- 446 in sub-Saharan African countries: evidence from Kenya, Lesotho and Tanzania. *Health Policy*
447 *Plan.* 2014 Oct;29(7):938–49.
- 448 41. Sia D, Onadja Y, Hajizadeh M, Heymann SJ, Brewer TF, Nandi A. What explains gender
449 inequalities in HIV/AIDS prevalence in sub-Saharan Africa? Evidence from the demographic and
450 health surveys. *BMC Public Health.* 2016 Dec 3;16(1):1136.
- 451 42. Horton KC, MacPherson P, Houben RMGJ, White RG, Corbett EL. Sex Differences in
452 Tuberculosis Burden and Notifications in Low- and Middle-Income Countries: A Systematic
453 Review and Meta-analysis. *PLoS Med.* 2016 Sep;13(9):e1002119.
- 454 43. MacNab YC. On Gaussian Markov Random Fields and Bayesian disease mapping. Lawson AB,
455 editor. *Stat Methods Med Res.* 2011 Feb 14;20(1):49–68.
- 456 44. Cuadros DF, Li J, Branscum AJ, Akullian A, Jia P, Mziray EN, et al. Mapping the spatial
457 variability of HIV infection in Sub-Saharan Africa: Effective information for localized HIV
458 prevention and control. *Sci Rep.* 2017 Dec 22;7(1):9093.
- 459 45. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for Tuberculosis Elimination. *Annu Rev*
460 *Public Health.* 2013 Mar 18;34(1):271–86.
- 461 46. Nardell E, Dharmadhikari A. Turning off the spigot: reducing drug-resistant tuberculosis
462 transmission in resource-limited settings. *Int J Tuberc Lung Dis.* 2010 Oct;14(10):1233–43.

463 **List of figure legends**

- 464 Figure 1: Temporal trend of co-infection risk by gender
- 465 Figure 2: Spatial patterns of co-infection burden by gender
- 466 Figure 3: Temporal trend of co-infection by age-category
- 467 Figure 4: Spatial patterns of co-infection burden by age category

468 Figure 5: Temporal trend of co-infection risk in Kenya

469 Figure 6: Spatial pattern of co-infection burden per County (2012 - 2018)

470 Figure 7: Relative risk plot (2012-2018)

471 Figure 8: County-specific relative risks and posterior probabilities

472 (a) Spatial pattern of coinfection risk

473 (b) Uncertainty for the spatial effect

474 Figure 9: Posterior probabilities for the space-time interaction: 47 counties and 2012-2018 years

475 **List of tables legends**

476 Table 1: Demographic characterization of TB patients with and without HIV in Kenya (2012–2018)

477 Table 2: Posterior estimates and their 95% credible intervals (CI) for the random effects models

478 Table 3: Posterior estimates and their 95% credible intervals (CI) for the random effects models with
479 covariates

Figures




Figure 1

Temporal trend of co-infection risk in Kenya




Figure 2

Temporal trend of co-infection risk by gender and age-category




Figure 5

Spatial patterns of co-infection burden by age category




Figure 6

County-specific relative risks and posterior probabilities. (a) Spatial pattern of coinfection risk (b) Uncertainty for the spatial effect




Figure 7

Posterior probabilities for the space-time interaction: 47 counties and 2012-2018 years